Abstract
BackgroundThe 2010 EULAR Recommendations have been updated last year, abatacept (ABT) has become available as the first biologic agent for patients with RA (1). The long term efficacy and safety...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have